



www.genfit.com

THE UNIVERSITY OF LILLE 2 STRENGTHENS ITS PARTICIPATION IN GENFIT

Lille (France), Cambridge (Massachusetts, United States), November 2, 2011– GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a €500,000 private placement reserved to one of its historical shareholders, the University of Lille 2.

The operation, performed on October 28, 2011 according to the delegations granted to the Management Board by the seventh and eighth resolutions adopted by the Extraordinary General Meeting held on September 28, 2011, follows the recent clinical results obtained for GFT505, the Company's leading drug candidate, that is currently at the beginning of Phase IIb clinical trials.

156,250 new shares have been issued in connection with this operation. The new shares are assimilated with existing shares immediately after settlement. The capital is made of 13,580,578 shares after the operation.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, ...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr